52239-89-1

Basic information

• Product Name: 3(2H)-Pyridazinone, 6-[1,1'-biphenyl]-4-yl-4,5-dihydro-
• CAS NO: 52239-89-1
• Molecular Formula: C16H14N2O
• Molecular Weight: 250.3
• Mol File: 52239-89-1.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 3(2H)-Pyridazinone, 6-[1,1'-biphenyl]-4-yl-4,5-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 3(2H)-Pyridazinone, 6-[1,1'-biphenyl]-4-yl-4,5-dihydro-(52239-89-1)
• EPA Substance Registry System: 3(2H)-Pyridazinone, 6-[1,1'-biphenyl]-4-yl-4,5-dihydro-(52239-89-1)

Safety Data

• Hazardous Substances Data: 52239-89-1(Hazardous Substances Data)

Upstream product

• 1444009-38-4 4-biphenyl-3-yl-4-oxo-butyric acid 
• 92-52-4 biphenyl 
• 36330-85-5 3-(p-phenyl)benzoylpropionic acid 
• 54011-27-7 methyl 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoate 

Downstream Products

• 1268133-98-7 3-phenyl-6-(4'-biphenyl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1268134-00-4 3-(4'-tolyl)-6-(4'-biphenyl)-1,2,4-triazolo[4,3-b]pyridazine 
• 88490-32-8 (6-biphenyl-4-yl-pyridazin-3-yl)-hydrazine 
• 1427435-46-8 7-(biphenyl-4-yl)-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-imine 
• 1427435-47-9 7-(biphenyl-4-yl)-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-one 
• 1445852-86-7 C₁₇H₁₆N₂O₂ 
• 1427435-48-0 7-(biphenyl-4-yl)-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-thione 
• 1456921-54-2 6-biphenyl-4-yl-2-(2-benzotriazol-1-ylethyl)-4,5-dihydropyridazin-3(2H)-one 
• 1365358-51-5 6-biphenyl-4-yl-(2-indol-1-ylethyl)-4,5-dihydropyridazin-3(2H)-one 
• 377047-49-9 6-biphenyl-3-chloropyridazine 

Relevant articles and documents

Synthesis, anti-convulsant activity and molecular docking study of novel thiazole pyridazinone hybrid analogues

Pyridazinone analogues have been known to be potential candidates for anticonvulsant agents. We have identified several pyridazinone-based anticonvulsant agents. As a continuation to our previous research, a series of hybrid pyridazinone-thiazole connected through amide linkage were designed and synthesized. Among these, compound SP-5F demonstrated significant anticonvulsant activity with median effective dose of 24.38 mg/kg (MES) and 88.23 mg/kg (scPTz). Results of GABA estimation showed a marked increase in the GABA level when compared with control. Molecular docking studies at the active site of GABA receptor, further confirmed the GABA modulatory effects of SP-5F.

Design, synthesis and antihypertensive screening of novel pyridazine substituted s-triazin-2-imine/one/thione derivatives

Some new 7-substituted-phenyl-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-imine/one/thione derivatives were synthesized by a sequence of reactions starting from appropriate aryl hydrocarbons. The final compounds were screened for antihypertensive activities by non-invasive method using Tail Cuff method. All the test compounds showed significant antihypertensive activity; 7-(biphenyl-4-yl)-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-imine (4p) exhibited antihypertensive activity more than the reference standard drugs.

Anticonvulsant and antitubercular activities of 6-Phenyl/Biphenyl-4-yl-2- [2-(pyridin-2-ylamino)-ethyl]-and 6-(Biphenyl-4yl)-2-(2N-subtituted amin-1-yl)-ethyl derivatives of 4,5-dihydropyridazin-3(2H)-one

Some 6-Phenyl/Biphenyl-4-yl-2-[2-(pyridin-2-ylamino)-ethyl]/-2-(2N- subtituted amin-1-yl)-ethyl-4,5- dihydropyridazin-3(2H)-one (4a-h) were synthesized by reacting 6-phenyl/biphenyl-4,5-dihydropyridazin-3(2H)-one with bromoethyl derivatives of cyclic secondary amines and 2-aminopyridine. All the compounds, 4a-h, were evaluated as anticonvulsant by using maximum electro shock (MES) and isoniazid (INH) induced convulsion methods at 50mg/kg dose level, and as antitubercular by Microplate Almar Blue Assay (MABA) method. In anticonvulsant activity, phenytoin (25mg/kg) and sodium vaproate (50mg/kg) were used as reference drugs. All compounds (4a-h) showed significant anticonvulsant activities against both MES and INH methods, and compound g showed highest activity against MES method. In antitubercular activity, compounds 4c-4h showed 25 μg/ml MIC value, and compounds 4a-4b exhibited 50 μg/ml MIC value when compared with reference drugs [isoniazid (3.125 μg/ml), pyrizinamide (3.125μg/ml)] and (streptomycin 6.25μg/ml) MIC values, and found less potent than the reference drugs.